Method for Treating a Cancer Based on Inflammatory Subtype Thereof
AssigneeUniversity of Baltimore, Maryland
InventorRania H. Younis
Life of this patent
Estimating the term…
Abstract
Provided herein is a method for treating a cancer in a subject by quantitating the concentration of a soluble form of Semaphorin 4D (sSema4D) in a blood sample obtained from the subject and administering an immunotherapy when the blood concentration of sSema4D is below a threshold value of 155 ng/ml. Also provided is a method for determining the continued susceptibility of a tumor tissue to immunotherapy in a subject by identifying the inflammatory subtype of the tumor tissue from a blood sample from the subject and administering immunotherapy over at least one interval as long as the tumor tissue exhibits an inflamed subtype.
Claims20
A method for treating a cancer in a subject in need thereof, comprising the steps of:
- a) obtaining a blood sample from the subject;
- b) quantitating a concentration of a soluble form of Semaphorin 4D (sSema4D) in the blood sample;
- and
- c) administering an immunotherapy to the subject when the concentration of sSema4D is below a threshold value.
A method for treating a cancer in a subject in need thereof, comprising the steps of:
- a) obtaining a blood sample from the subject;
- b) measuring a concentration of a soluble form of Semaphorin 4D (sSema4D) in the blood sample;
- c) administering an immunotherapy to the subject when the concentration of the sSema4D is below 155 ng/ml;
- and
- d) repeating steps a to c during at least one interval.
A method for determining the continued susceptibility of a tumor tissue to immunotherapy in a subject in need thereof, comprising:
- a) identifying an inflammatory subtype of the tumor tissue from a first blood sample obtained from the subject;
- b) administering an immunotherapy to the subject when the inflammatory subtype is identified as an inflamed subtype;
- c) obtaining at least a second blood sample from the subject during at least one interval after administering the immunotherapy;
- and
- d) identifying the inflammatory subtype wherein, if the inflammatory subtype is the inflamed subtype, the tumor tissue continues to be susceptible to the immunotherapy.
Dependencies are inferred from the claim text.